share_log

HC Wainwright & Co. Downgrades Taro Pharmaceutical Indus to Neutral, Maintains Price Target to $43

Moomoo 24/7 ·  Jan 18 06:15

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Taro Pharmaceutical Indus (NYSE:TARO) from Buy to Neutral and maintains the price target from $43 to $43.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment